Following the development for liquid biopsies of the SiRe next-generation sequencing (NGS) panel that covers 568 clinical relevant mutations in EGFR, KRAS, NRAS, BRAF, cKIT and PDGFRa genes, in this current study, we apply this small NGS panel on tissue samples of lung cancer.
Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples / Pepe, Francesco; De Luca, Caterina; Smeraglio, Riccardo; Pisapia, Pasquale; Sgariglia, Roberta; Nacchio, Mariantonia; Russo, Maria; Serra, Nicola; Rocco, Danilo; Battiloro, Ciro; Ambrosio, Francesca; Gragnano, Gianluca; Vigliar, Elena; Bellevicine, Claudio; Troncone, Giancarlo; Malapelle, Umberto. - In: JOURNAL OF CLINICAL PATHOLOGY. - ISSN 0021-9746. - 72:1(2019), pp. 38-45-45. [10.1136/jclinpath-2018-205386]
Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples
Pepe, Francesco;De Luca, Caterina;Smeraglio, Riccardo;Pisapia, Pasquale;Sgariglia, Roberta;Nacchio, Mariantonia;Russo, Maria;Serra, Nicola;Gragnano, Gianluca;Vigliar, Elena;Bellevicine, Claudio;Troncone, Giancarlo;Malapelle, Umberto
2019
Abstract
Following the development for liquid biopsies of the SiRe next-generation sequencing (NGS) panel that covers 568 clinical relevant mutations in EGFR, KRAS, NRAS, BRAF, cKIT and PDGFRa genes, in this current study, we apply this small NGS panel on tissue samples of lung cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
